Patent details

EP2314321 Title: Formulations comprising antisense nucleotides to connexins

Basic Information

Publication number:
EP2314321
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP100131804
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
Formulations comprising antisense nucleotides to connexins
French Title of Invention:
Formulation comprenant des nucléotides antisens contre les connexines
German Title of Invention:
Formulierungen enthaltend Antisense Nukleotide spezifisch für Connexine
SPC Number:

Dates

Filing date:
27/01/2000
Grant date:
04/06/2014
EP Publication Date:
04/06/2014
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
27/04/2011
EP B1 Publication Date:
04/06/2014
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
27/01/2019
Expiration date:
27/01/2020
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
27/01/2000
 
 

Name:
Coda Therapeutics Inc.
Address:
12520 High Bluff Drive Suite 350 San Diego, CA 92130, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
28/08/2014
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
Becker David Laurence
Address:
United Kingdom (GB)

2

Name:
Green Colin Richard
Address:
New Zealand (NZ)

Priority

1

Priority Number:
33392899
Priority Date:
27/01/1999
Priority Country:
New Zealand (NZ)

2

Priority Number:
50019099
Priority Date:
07/10/1999
Priority Country:
New Zealand (NZ)

Classification

Main IPC Class:
A61K 48/00;

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
08/01/2018
Last Annual Fee Paid Number:
19
Last Annual Fee Paid Amount:
281 Euro
Payer:
MARKS & CLERK LLP
Filing date Document type Number of pages
31/05/2019 Outgoing Correspondence 1